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Summary
 
T lymphocytes express several low molecular weight transmembrane adaptor proteins that re-
cruit src homology (SH)2 domain–containing intracellular molecules to the cell membrane via
tyrosine-based signaling motifs. We describe here a novel molecule of this group termed SIT
(SHP2 interacting transmembrane adaptor protein). SIT is a disulfide-linked homodimeric gly-
coprotein that is expressed in lymphocytes. After tyrosine phosphorylation by src and possibly
syk protein tyrosine kinases SIT recruits the SH2 domain–containing tyrosine phosphatase
SHP2 via an immunoreceptor tyrosine-based inhibition motif. Overexpression of SIT in Jurkat
cells downmodulates T cell receptor– and phytohemagglutinin-mediated activation of the nu-
clear factor of activated T cells (NF-AT) by interfering with signaling processes that are proba-
bly located upstream of activation of phospholipase C. However, binding of SHP2 to SIT is
not required for inhibition of NF-AT induction, suggesting that SIT not only regulates NF-AT
activity but also controls NF-AT unrelated pathways of T cell activation involving SHP2.
Key words: T lymphocytes • T cell receptor • transmembrane adaptor proteins • signal 
transduction
 
A
 
fter binding of peptide–MHC to the TCR complex, a
cascade of biochemical events is initiated that lead fi-
nally to T cell proliferation (1, 2). Among the earliest sig-
nals that can be detected after triggering of the TCR are
 
increases in enzymatic activities of cytoplasmic protein tyro-
sine kinases (PTKs),
 
1
 
 including the src kinases p56
 
lck
 
 and
p59
 
fyn
 
 as well as the syk-related PTKs p62
 
syk
 
 and ZAP70.
These tyrosine kinases phosphorylate intracellular proteins
that transmit the signal further into the intracellular envi-
ronment (3, 4). Among a plethora of intracellular molecules
becoming tyrosine phosphorylated, several polypeptides
have been identified that are collectively called adaptor pro-
teins (for review see references 5–7). According to their
definition, adaptor proteins lack an enzymatic function but
are capable of mediating noncovalent protein–protein in-
teractions with other signal-transducing molecules via tyro-
sine-based signaling motifs (8) or modular binding domains
(e.g., src homology [SH]2, SH3, pleckstrin homology, WW,
phosphotyrosine [PTYR]-binding, and PDZ domains; ref-
erences 9–12). Adaptor proteins expressed in T lympho-
cytes include Grb2, src homologous and collagen protein
(SHC), SH2 domain–containing leukocyte phosphoprotein
(SLP)-76, SLP-76–associated phosphoprotein (SLAP)-130,
src kinase–associated phosphoprotein (SKAP)55, and SKAP-
homologue (HOM) (13–19).
Most recently, experimental evidence has been accumu-
lated showing that besides cytoplasmic adaptor proteins, T
lymphocytes express low mol wt transmembrane proteins
that are characterized by short extracellular domains and
comparably long cytoplasmic tails. The cytoplasmic do-
mains of these polypeptides contain tyrosine based signaling
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Abbreviations used in this paper:
 
 aa, amino acid; EST, expressed sequence
tag; Grb2, growth factor receptor binding protein 2; IEF, isoelectric fo-
cusing; ITAM, immunoreceptor tyrosine-based activation motif; ITIM,
immunoreceptor tyrosine based inhibition motif; LAT, linker for activa-
tion of T cells; NF-AT, nuclear factor of activated T cells; PI3-K, phos-
phatidylinositol 3-kinase; PLC, phospholipase C; PTK, protein tyrosine
kinase; PTYR, phosphotyrosine; SH, src homology; SHIP, SH2 contain-
ing inositol phosphatase; SHP, SH2 containing protein tyrosine phos-
phatase; SIT, SHP2-interacting transmembrane adaptor protein; SLP,
SH2 domain containing leukocyte phosphoprotein; TRIM, T cell recep-
tor–interacting molecule. 
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motifs (distinct from ITAMs) that probably mediate interac-
tions with the SH2 domains of intracellular signaling mole-
cules. We had suggested calling this novel group of polypep-
tides transmembrane adaptor proteins (20). Before now, two
transmembrane adaptor molecules have been described,
namely the recently cloned proteins LAT (linker of activation
of T lymphocytes) and TRIM (T cell receptor–interacting
molecule) (20–22). Both LAT and TRIM are reported to as-
sociate with intracellular signaling molecules (e.g., Grb2,
phospholipase C [PLC]-
 
g
 
, SLP-76, and phosphatidylinosi-
tol 3 kinase [PI3-K]) after tyrosine phosphorylation.
In this study we report the identification, nanoelectro-
spray tandem mass spectrometry sequencing, molecular clon-
ing, and functional characterization of a novel transmembrane
adaptor protein termed SIT (SHP2-interacting transmem-
brane adaptor protein). SIT represents a disulfide-linked
homodimeric lymphocyte-specific glycoprotein with a short
extracellular domain of 18 amino acids (aa) possessing a sin-
gle N-linked glycosylation site, a 20-aa transmembrane re-
gion, and a 136-aa cytoplasmic tail. The cytoplasmic do-
main of SIT contains five tyrosine-based signaling motifs
that could mediate SH2 domain–dependent interactions
with intracellular signaling molecules. Indeed, after T cell
activation, SIT associates with the SH2 domain–containing
cytoplasmic tyrosine phosphatase SHP2 via an ITIM. Im-
portantly, overexpression of SIT in Jurkat cells downmod-
ulates TCR- and PHA-mediated induction of nuclear
factor of activated T cells (NF-AT) activity. In contrast, in-
duction of NF-AT activity after triggering of the G pro-
tein–coupled muscarinic receptor is not influenced by
overexpression of SIT. These data suggest that SIT is prob-
ably involved in an unknown signaling pathway that regu-
lates transcriptional activity of NF-AT upstream of PLC.
However, overexpression of a mutated form of SIT lacking
the SHP2 binding site revealed that the association between
SIT and SHP2 is not required for SIT-mediated inhibition
of NF-AT activity. Therefore, we propose that SIT not
only regulates the transcriptional activity of NF-AT, but
also controls NF-AT unrelated pathways of T cell activa-
tion that involve SHP2.
 
Materials and Methods
 
Purification of gp30/40.
 
Purification of gp30/40, in-gel diges-
tion, nanoelectrospray tandem mass spectrometric sequencing,
and assembly of peptide sequence tags for database searching have
been described previously (20, 23–26). Peptide esterification was
performed on a part of the unseparated digest by treatment with
2 M HCl in aqueous-free methanol for 45 min at room tempera-
ture. After derivatization, the reaction mixture was dried in a
vacuum centrifuge.
 
cDNA Cloning.
 
Based on an expressed sequence tag (EST)
cDNA sequence corresponding to the (YSEVV(L/I)DSEPK) pep-
tide obtained by nanoelectrospray sequencing of purified pp29/30,
forward and nested forward oligonucleotides (CCTGCCAG-
GGCTGCAGAGGAGGTG and CCCCGAGCCGGAGCTC-
TATGCCTC) and reverse and nested reverse oligonucleotides
(TGCGGGTCTGGGCACATACTGAGGC and CACCTCCT-
CTGCAGCCCTGGCAGG) were used for 3
 
9
 
- and 5
 
9
 
-rapid
 
amplification of cDNA end (RACE) reactions as previously de-
scribed (20). The resulting products were purified from agarose
gels and sequenced directly. 5
 
9
 
- and 3
 
9
 
-specific primers corre-
sponding to the deduced untranslated regions were used to am-
plify the complete cDNA, which was double-strand sequenced.
For cloning of murine gp30/40, a partial cDNA was generated
using 5
 
9
 
 and 3
 
9
 
 primers (CAGCAACTTTGACACTGTCAGTG
and ATCCGACCTTGAGCTGGTCGC, respectively) deduced
from a mouse gp30/40 EST clone. The fragment was then used
for screening a mouse genomic library (provided by Dr. K. Pfeffer,
Technical University, Munich, Germany). Resulting clones were se-
quenced and primers specific for the putative 5
 
9
 
 and 3
 
9
 
 untranslated
regions were used to amplify murine gp30/40 from mouse thy-
mocyte cDNA. The resulting fragment was gel-purified and double-
strand sequenced. All sequencing reactions and computer-assisted se-
quence analysis were performed as previously described (20).
 
cDNA Constructs.
 
The coding region of human wild-type
gp30/40 was amplified from HPB-ALL cells cDNA using 5
 
9
 
 and
3
 
9
 
 specific forward and reverse primers (CCCTCGAGCTATGA-
ACCAGGC TGACCCTCGGC and CCTCGAGCTCTACG-
GGGGGCTGGGGCAGTG, respectively). The purified fragment
was cloned into the expression vector pEF-BOS (27). The chimeric
CD8–gp30/40 construct (CCG chimera) consists of the extracellu-
lar and transmembrane regions (aa 1–145) of CD8
 
a
 
 fused to resi-
dues 65–196 of human gp30/40 (see Fig. 6). It was generated by
separately amplifying the cDNA encoding the extracellular and
transmembrane domains of CD8
 
a
 
 using a CD8
 
a
 
-specific 5
 
9
 
 primer
(ATGGCCTTACCAGTGACCGCCTTG), a chimeric 3
 
9
 
 primer
(GCTCCGGCCCCTGGTCCACTGGGACAAGTGGTTGCA-
GTAAAGGGTGATA ACCAG) and the gp30/40 fragment with
an overlapping 5
 
9
 
 primer (GCTCCGGCCCCTGGTCCACTG-
GGACAAGTGGTTGCAGTAAAGGGTGATAACCAG) and a
gp30/40-specific 3
 
9
 
 primer (see above). The two overlapping frag-
ments were used as templates for a chimeric PCR with CD8
 
a
 
-5
 
9
 
and gp30/40-3
 
9
 
 primers. Mutants of gp30/40 and the CCG chi-
mera were produced by site-directed mutagenesis using the Quick
Change site-directed mutagenesis kit (Stratagene) according to
the manufacturer’s procedure. The following mutants were used
in this study: gp30/40-N
 
®
 
Q (N
 
26
 
 to Q), gp30/40-ITIM (Y
 
148
 
 to
F), gp30/40-STOP (where a FLAG-tag coding sequence followed
by a stop codon was inserted after H
 
62
 
), CC-ITIM (Y
 
148
 
 to F),
and CC-STOP (S
 
71
 
 to stop codon). The sequence of all con-
structs was confirmed by double-strand sequencing.
 
Northern Blot Analysis.
 
Human multiple-tissue Northern blots
(Clontech) were probed with full-length radiolabeled cDNA of
gp30/40 under stringent conditions according to the manufac-
turer’s instructions.
 
Cells and Antibodies.
 
Cells were cultured in RPMI 1640 sup-
plemented with 10% FCS, 1% penicillin-streptomycin, and 2%
glutamine (GIBCO BRL, Germany). The Jurkat variant CCG
(stably expressing the CCG chimera) was established as described
elsewhere (20). The Jurkat variant J.HM1.2.2 (27–30), which is
stably transfected with the human muscarinic receptor type 1,
was provided by Dr. Arthur Weiss, University of California at
San Francisco, San Francisco, CA, with the authorization of Gen-
entech Inc., and was cultured under standard conditions.
The polyclonal antiserum directed at gp30/40 was generated by
immunizing rabbits with a KLH-coupled synthetic peptide corre-
sponding to aa 96–114 of gp30/40. Affinity purification of the anti-
serum was performed as previously described (31). SHP2, MAP ki-
nase, PTYR (4G10) Abs (Upstate Biotechnology Inc.), myc (9E10,
a gift from Dr. D. Cantrell, Imperial Cancer Research Fund, Lon-
don, UK), and FLAG (M2, Kodak) Abs were used at 1 
 
m
 
g/ml for 
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Western blotting, and rabbit p59
 
fyn
 
 and p56
 
lck
 
 antisera (provided by
Dr. A. Veillette, McGill Cancer Center, McGill University, Mon-
treal, Canada) were diluted 1:2,000 (vol/vol). CD3-
 
e
 
 (OKT3,
IgG2a) or TCR (C305, IgM, provided by Dr. A. Weiss) mAbs were
used at 5 
 
m
 
g/ml or as hybridoma supernatant, respectively. The
polyclonal antiserum directed at lymphocyte phosphatase–associated
phosphoprotein has been described previously (31) and was used at a
1:5,000 dilution for Western blot analysis. For immunoprecipitation
experiments, protein A–Sepharose-purified PTYR (PY72, provided
by Dr. B. Sefton, Salk Institute, San Diego, CA), CD3-
 
e
 
, or CD8
(AICD8.1, IgG1) mAbs were covalently coupled to cyanogen bro-
mide–activated Sepharose beads (6 mg/ml packed beads). Typically,
15 
 
m
 
l of packed coupled beads were used for immunoprecipitation.
 
Precipitation Experiments.
 
Cells were activated with culture
supernatant of C305 mAb or a combination of biotinylated CD3-
 
e
 
plus CD4 Abs (10 
 
m
 
g/ml each) followed by cross-linking with
avidin (80 
 
m
 
g/ml), PHA (1 
 
m
 
g/ml), 0.1 mM Na Vanadate plus
1 mM H
 
2
 
O
 
2
 
 at 37
 
8
 
C. Immunoprecipitations were performed using
gp30/40 antiserum (1:100 vol/vol dilution) followed by protein
A–Sepharose, or using CD8, CD3, or anti-PTYR mAb-coupled
beads, as described elsewhere (20). Alternatively, the isolated SH2
domain of SHP2 (provided by Dr. B. Neel, Beth Israel Deaconess
Medical Center, Boston, MA), was expressed as glutathione-
 
S
 
-transferase (GST) fusion protein and used for precipitation
experiments as previously reported (17, 32). After washes, the in-
dividual precipitates were subjected to SDS-PAGE and further
processed by Western blot analysis. In vitro kinase assay, repre-
cipitation of in vitro phosphorylated proteins, two-dimensional
gel electrophoresis, and Western blot analysis were performed as
previously described (20, 33).
 
Deglycosylation Experiment.
 
In vitro–labeled gp30/40 was ob-
tained from a primary CD3 immunoprecipitate by reprecipitation
using gp30/40 antiserum as reported elsewhere (31). The repre-
cipitated material was subjected to SDS-PAGE and the position
of SIT was determined by autoradiography. The corresponding
band was excised from the dried gel, electroeluted, precipitated
with acetone, and subjected to deglycosylation using endoglyco-
sidase F (Boehringer Mannheim) as previously described (34).
 
Preparation of Membrane and Cytosolic Fractions.
 
Jurkat cells
(7.5 
 
3 
 
10
 
7
 
) were stimulated with 0.1 mM pervanadate plus 1 mM
H
 
2
 
O
 
2
 
 for 2 min at room temperature. After one wash in cold
TBS, cells were resuspended in 1 ml of hypotonic buffer (50 mM
Tris-HCl, pH 7.5, 10 mM KCl, 1 mM CaCl
 
2
 
, 1 mM MgCl
 
2
 
, 1 mM
vanadate, 1 mM PMSF, 1 
 
m
 
g/ml aprotinin, and 1 
 
m
 
g/ml leupep-
tin) and left on ice for 45 min. After sonication, cells were spun
down for 15 min at 15,000 rpm and 4
 
8
 
C. Supernatant (
 
5 
 
total
lysate) was adjusted to 5 ml with hypotonic buffer and centrifuged
for 40 min at 33,000 rpm and 4
 
8
 
C using a SW55Ti rotor. The su-
pernatant (
 
5 
 
cytosol) was collected, supplemented with detergent
and NaCl to reach final concentrations of 1% NP-40 and 150 mM
NaCl, respectively, and further processed for anti-gp30/40 immu-
noprecipitation. The pellet (
 
5 
 
membrane fraction) was washed in
5 ml of high salt buffer (50 mM Tris-HCl, pH 7.5, 500 mM NaCl,
1 mM vanadate, 1 mM PMSF, 1 
 
m
 
g/ml aprotinin, and leupeptin),
solubilized in lysis buffer containing 1% NP-40, and subjected to
anti-gp30/40 immunoprecipitation as previously described.
 
Laserscan Microscopy.
 
The confocal laserscan microscopy of
HPB-ALL cells and Jurkat cells was essentially performed as de-
scribed previously (20) with the exception that for the experi-
ments shown in panels 5 and 6 of Fig. 4 A a mixture of affinity-
purified SIT (5 
 
m
 
g/ml) and CD8 (AICD8.1, IgG1, 10 
 
m
 
g/ml) Abs
was used, whereas all other experiments shown in Fig. 4 were per-
formed using 20 
 
m
 
g/ml of affinity-purified SIT antibody.
 
Transfection of COS Cell.
 
COS cells were transfected as pre-
viously reported (20). The constructs used were as follows: wild-
type Fyn (T) or Lck cloned in pSR
 
a
 
 expression vector (provided
by Dr. A. da Silva, Dana Farber Cancer Center, Boston, MA),
FLAG-tagged Syk cloned into the p5C7 vector (donated by Dr.
W. Kolanus, Gene Center, Munich, Germany), and myc-tagged
ZAP70 inserted into the pcDNA3 vector (a gift from Dr. R.
Abraham, Mayo Clinic, Rochester, MN).
 
Luciferase Reporter Gene Assay.
 
Jurkat cells or J.HM1.2.2 cells
were transfected as previously described (20), using 30 
 
m
 
g of the
indicated cDNA construct together with 10 
 
m
 
g of the NF-AT lu-
ciferase reporter construct. At 18 h after transfection, 8 
 
3 
 
10
 
4
 
 cells/
well were stimulated in duplicates with medium, PHA (1 
 
m
 
g/ml),
PMA (10
 
2
 
8 
 
M) plus ionomycin (1 
 
m
 
g/ml), immobilized anti-
TCR mAb C305, or carbachol (500 
 
m
 
M, Sigma Chemical Co.)
in a 96-well plate (U96 Maxisorp, Nunc immunoplate). After 6 h
of stimulation cells were harvested, washed twice in PBS, and
lysed for 15 min at room temperature. After centrifugation, 30 
 
m
 
l
of the supernatants were analyzed as duplicates for luciferase ac-
tivity using a luminometer (Berthold Lumat 9507). Luciferase
activity is expressed as percentage of the maximal promoter activ-
ity induced by incubating the transfected cells with PMA plus
ionomycin.
 
Results
 
Purification of gp30/40 and Cloning of the Corresponding
cDNA.
 
We have recently reported the molecular cloning
of a novel disulfide-linked transmembrane adaptor protein,
called TRIM, that associates with the TCR–CD3–
 
z
 
 complex
in T lymphocytes (20). Four proteins were copurified with
TRIM, namely three caseins as well as an additional protein
that could not be identified by searching comprehensive data-
bases using a tryptic peptide sequence tag (23). Therefore de
novo sequencing of peptides was performed after esterifica-
tion of the original tryptic digest as previously described
(24, 26). The fragmentation spectrum of peptide T
 
1
 
 (Fig. 1
A) yielded complete aa sequences, whereas those of peptide
T
 
2
 
 and T
 
3
 
 yielded only partial aa sequences. Searching EST
databases with the sequence YSEVV(L/I)DSEPK determined
for peptide T
 
1
 
 resulted in the identification of an EST coding
for this peptide as well as for additional 73 aa that all belonged
to an as yet undescribed polypeptide. Reverse and forward
oligonucleotides deduced from the EST sequence were used
in 5
 
9
 
 and 3
 
9
 
 RACE experiments, respectively, to amplify the
rest of the corresponding gene.
An open reading frame of 588 nucleotides (data not
shown) codes for a protein of 196 aa (Fig. 1 B). The first 22
NH
 
2
 
-terminal residues of the newly identified protein are
hydrophobic, suggesting that they could represent a leader
peptide required for transmembrane transport. A putative
extracellular domain comprising 18 aa contains one poten-
tial site for N-linked glycosylation (N
 
26
 
) as well as one cys-
teine residue (C
 
27
 
), which could be involved in the formation
of an interchain disulfide bond. Residues 41–60 are highly
hydrophobic and probably represent a transmembrane do-
main. The putative cytoplasmic portion of the protein (resi-
dues 61–196) contains several potential phosphorylation sites
for protein kinase C (T
 
98
 
) and/or for casein kinase II (S
 
83 
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and S
 
182
 
). Importantly, it also contains six tyrosine residues,
five of which could be involved in SH2 domain–mediated
protein–protein interactions after phosphorylation. Two
of these tyrosine residues represent YxxL/V-motifs (Y127
and Y169), indicating the possibility of a phosphorylation-
dependent interaction with SH2 domains of src PTKs. In
addition, tyrosines Y90 and Y188 are potential binding sites
for the SH2 domain of the adaptor molecule Grb2. Finally,
the cytoplasmic portion of the novel molecule possesses
one potential ITIM (VxY148xxV), which might mediate in-
teractions with the SH2 domains of cytoplasmic tyrosine
phosphatases like SHP1 and SHP2 or with the inositol phos-
phatase SHIP (35, 36). It is noteworthy to mention that tyro-
sine-based sequence motifs with similarity to the EEVPLY90
GNL and the MCY127TSL motif are also present in the
cytoplasmic portion of TRIM (EDTPIY63GNL motif and
MCY110ASL motif, respectively). This could indicate that
both polypeptides partially interact with the same proteins
in T lymphocytes. In addition, similar to TRIM, the trans-
membrane region of the novel protein contains the se-
quence motif WGxxxxxG, which shows some similarity to
a recently described dimerization motif in a-helices (37).
Comparison of the predicted aa sequence of the new pro-
tein (preliminarily termed gp30/40) with all available data-
bases did not reveal a significant homology with any known
polypeptides (with the exception of TRIM, see above).
The mouse homologue of gp30/40 was identified by us-
ing a mouse EST obtained from an EST database for screen-
ing a genomic library. The sequence information from pos-
itive clones was then used to generate the complete mouse
cDNA by PCR. A comparison between the mouse and hu-
man aa sequences (Fig. 1 B) revealed that all five tyrosine-
based signaling motifs as well as the putative dimerization
motif in the transmembrane domains are conserved between
the two species. However, in contrast to the human pro-
tein, mouse gp30/40 lacks a leader peptide.
gp30/40 Represents a Disulfide-linked Dimeric Glycoprotein.
Previous data suggested that gp30/40, like TRIM, repre-
sents a disulfide-linked dimer that associates with the
TCR–CD3–z complex under mild detergent conditions
(20, 33). To further characterize gp30/40, HPB-ALL cells
were lysed in Brij58 containing lysis buffer to preserve
weak protein–protein interactions. Postnuclear lysates were
subjected to CD3 immunoprecipitation followed by in
vitro kinase assay. 10% of the in vitro–labeled immuno-
precipitate was directly loaded onto two-dimensional IEF/
SDS-PAGE, and the remaining 90% were incubated with
lysis buffer containing 1% Triton X-100 plus 0.5% SDS in
order to release the in vitro–labeled proteins from the pri-
mary immunoprecipitate (33). The released material was
then subjected to reprecipitation using a polyclonal anti-
gp30/40 antibody which was raised in rabbits immunized
Figure 1. Sequencing of the gel-purified gp30/40 by nanoelec-
trospray tandem mass spectrometry and cloning of its correspond-
ing cDNA. (A) (Top) Part of the spectrum of the unseparated
in-gel tryptic digest of the previously described pp29/30. Peaks
designated with asterisks belong to trypsin autolysis products. All
peptide ions labeled in the spectrum were in turn isolated by the
first quadrupole mass analyzer of a triple quadrupole instrument
and fragmented in the collision cell, and their tandem mass spectra
were acquired. Peptide ions designated with T originate from
gp30/40. Peptides designated with t originate from TRIM. (Bot-
tom) Tandem mass spectrum of the doubly charged ion T1 with a mass to charge ratio (m/z) of 633.4. Upon their collisional fragmentation, tryptic pep-
tides produce continuous series of fragment ions containing the COOH terminus (Y”-ions). The peptide sequence is deduced by considering precise
mass differences between adjacent Y”-ions in the series. Y” ions dominate in the m/z region above the parent ion (M12H)21 and therefore the peptide
sequence could be determined unambiguously here. However, the m/z region below the parent ion is densely populated by fragment ions of different
type and origin. In this region it is not usually possible to extend the series of Y” ions to the COOH terminus of a peptide using the mass differences be-
tween the adjacent fragment ions as a guide. Therefore, additional data are required to confirm that a particular ion indeed belongs to the Y” series of
peptide fragments. To acquire this information, a part of the unseparated digest was esterified and tandem mass spectra of the peptides were acquired (data
not shown). Software assisted comparison of the tandem mass spectra of the derivatized peptides and the nonderivatized peptides enables determination of
peptide sequences with high confidence (25, 47). Note that after the full length sequence of gp30/40 had been obtained, the tandem mass spectra of the
ions T2 and T3 were retrospectively matched to the corresponding tryptic peptides. In addition, note that the shown sequence reads from the COOH ter-
minus to the NH2 terminus. (B) aa sequences of human and mouse gp30/40. The putative transmembrane regions are boxed. The tyrosine-based signaling
motifs are depicted underneath the corresponding sequences, and the peptide sequence obtained by nanoelectrospray tandem mass spectrometry is indi-
cated by a double line over the corresponding sequence. Tyrosine residues are underlined. The sequence data are available from EMBL/GenBank/DDBJ
under accession number AJ010059 (human) and AJ236881 (mouse).1185 Marie-Cardine et al.
with a KLH-coupled peptide corresponding to aa 96–114.
The two-dimensional IEF/SDS-PAGE analysis of the sec-
ondary immunoprecipitate shown in Fig. 2 A, panel 4, in-
dicates that the anti-gp30/40 antibody reprecipitates an in
vitro–labeled protein from the primary CD3 immunopre-
cipitate that produces at least four vertical stripes with mol
wt between 30 and 50 kD and differential isoelectric points
in IEF. These biochemical characteristics indicate that in
vitro–labeled gp30/40 is differentially phosphorylated on
several distinct phosphorylation sites and that its extracellu-
lar domain is highly glycosylated. Indeed, the deglycosyla-
tion experiment shown in Fig. 2 C demonstrates that en-
doglycosidase treatment of gp30/40 reduces its apparent
mol wt in SDS-PAGE from z40 to z20 kD. Thus, glyco-
sylation of the single asparagine residue in the extracellular
portion of gp30/40 accounts for z20 kD of mol wt. Fig. 2
B further demonstrates that gp30/40 represents a disulfide-
linked dimer as judged from its differential migration on
nonreducing versus reducing SDS-PAGE.
The data shown in Fig. 2, panels 1 and 2, explain why
we have not recognized the existence of gp30/40 as a part
of the CD3-associated signaling complex in our previous
studies. Thus, on a standard 1-h exposure of the in vitro–
labeled CD3 immunoprecipitate gp30/40 is not visible,
perhaps because of its migration in IEF/SDS-PAGE as a
diffuse and only weakly focusing polypeptide. Only upon
overexposure of the dried gels do the long stripes corre-
sponding to in vitro–labeled gp30/40 become visible (Fig.
2 A, panel 2). These properties of gp30/40 also provide
an explanation for the difficulties to analyze gp30/40 bio-
chemically (see below).
Tissue Distribution of gp30/40. Expression of the gp30/
40 gene was determined by Northern blot analysis using a
gp30/40 cDNA probe. The multiple tissue Northern blots
shown in Fig. 3 demonstrate that gp30/40 is strongly ex-
pressed in thymus and to a lesser extent in spleen and lymph
nodes. Upon overexposure of the shown blots, weak gp30/
40 mRNA signals are also detectable in peripheral blood
leukocytes and bone marrow (data not shown), indicating
that low amounts of gp30/40 are expressed not only in T
cells but also in other cells of hematopoietic origin. Indeed,
further analysis revealed that gp30/40 is expressed in the
HPB-ALL and Jurkat T cell lines and to a lower extent in
the B cell lines LAZ509 and SKW6.9, whereas it is not de-
tectable in monocytic cell lines HL-60 and U937, nor the
erythroleukemic cell line K562 (data not shown). These
data collectively suggest that gp30/40 is selectively ex-
pressed in lymphocytes.
Subcellular Localization of gp30/40. The aa sequence of
gp30/40 (Fig. 1 B) strongly suggested that it represents an
integral membrane protein. We attempted to assess the
subcellular localization of gp30/40 in the T cell lines HPB-
ALL and Jurkat (both expressing endogenous gp30/40) by
indirect immunofluorescence using an affinity-purified
gp30/40 antiserum. However, our attempts to localize en-
dogenous gp30/40 within the two cell lines remained un-
successful, perhaps because the amounts gp30/40 that are
constitutively expressed are too low to be detected by our
Figure 2. Biochemical characterization of gp30/40. (A) 107 HPB-ALL
cells lysed in Brij58-containing buffer were subjected to CD3 immuno-
precipitation followed by in vitro kinase assay. 10% of the in vitro–labeled
material was directly applied to two-dimensional IEF/SDS-PAGE (panels
1 and 2). The remaining 90% was subjected to reprecipitation using pre-
immune serum (panel 3) or immune anti-gp30/40 serum (panel 4). Panel
2 was overexposed to visualize gp30/40 in the CD3 immunoprecipitate.
(B) The same experiment except that the precipitates were analyzed by
one-dimensional SDS-PAGE under nonreducing (nr.) or reducing (red.)
conditions. (C) Deglycosylation experiment. In vitro–labeled gp30/40
was left untreated (2) or incubated with buffer supplemented with endo-
glycosidase F (1) followed by SDS-PAGE and autoradiography.
Figure 3. Tissue distribution of gp30/40. Northern blot analysis dem-
onstrating expression of gp30/40 in hematopoietic cells. A full-length
gp30/40 cDNA probe was used for hybridization.1186 The SHP2-interacting Transmembrane Adaptor Protein SIT
antiserum (for example see Fig. 6 A). To circumvent this
problem, we transiently overexpressed gp30/40 in Jurkat T
cells and COS cells. The transfectants were then permeabi-
lized with acetone and stained with affinity-purified gp30/40
antiserum. The specificity of the antiserum was proven in a
Jurkat variant stably expressing a chimeric gp30/40 mole-
cule in which the cytoplasmic part of gp30/40 was fused
to the extracellular and transmembrane domains of CD8
(CCG chimera, Fig. 4 A, panels 5 and 6). The confocal la-
ser scan images shown in Fig. 4 A, panels 1, 2 (Jurkat cells),
and 4 (COS cells) indicated that, as expected, gp30/40 ap-
pears to accumulate at the level of the plasma membrane.
No reactivity of the antiserum was seen in nontransfected
COS cells (Fig. 4 A, panel 3), ruling out the possibility of
nonspecific reactivity of the antiserum with a membrane
associated protein(s) unrelated to gp30/40.
To further prove membrane association of endogenously
expressed gp30/40 in nontransfected T cells, cytosolic and
high salt–washed membrane fractions were prepared from
pervanadate-treated Jurkat cells and subjected to gp30/40
immunoprecipitation followed by anti-PTYR Western blot
analysis. As shown in the left panel of Fig. 4 B, gp30/40 is
exclusively detectable in the membrane fraction, whereas
no signal was obtained when the immunoprecipitate was
prepared from the cytosolic fraction. The purity of the in-
dividual fractions was proven by Western blot analysis us-
ing antibodies directed at MAP kinase and the recently de-
scribed transmembrane protein LPAP. MAP kinase was
Figure 4. Subcellular localization of gp30/40. (A) Confocal laser scan
microscopy depicting the subcellular localization of gp30/40. Jurkat T
cells (panels 1 and 2) or COS cells (panels 3 and 4) were left untransfected
(panel 3) or were transiently transfected with a plasmid encoding wild-
type gp30/40 (panels 1, 2, and 4). The subcellular localization of gp30/40
was then assessed using an affinity-purified gp30/40 antiserum. Note that
panel 2 is an inverted image of panel 1 that allows visualization of cells
that express only very low levels of the transfected molecule. Panels 5 and
6 show specificity controls for the antiserum. Jurkat cells stably expressing
a chimeric gp30/40 molecule (the cytoplasmic part of gp30/40 fused to
the extracellular and transmembrane portions of human CD8, CCG chi-
mera) were incubated with gp30/40 (red fluorescence, Cy3, panel 5) and
CD8 (green fluorescence, Cy2, data not shown) antibodies. Panel 5 depicts the membrane localization of gp30/40 in CCG cells, and panel 6 shows the
colocalization of CD8 and gp30/40. (B) gp30/40 is an integral membrane protein. (Left) Cytosolic (C) and membrane (M) fractions were prepared from
pervanadate-treated Jurkat T cells and subjected to anti-gp30/40 immunoprecipitation. Precipitates were then separated by nonreducing SDS-PAGE and
analyzed by anti-PTYR Western blot. gp30/40 is visible under these experimental conditions as a broad band migrating between 60 and 90 kD. (Right)
Specificity controls. Aliquots of total lysates (L, 106 cells), the cytosolic fraction (C, 106 cells) and the membrane fraction (M, 5 3 106 cells) were separated
on reducing SDS-PAGE and sequentially immunoblotted with antibodies directed at MAP-kinase or the CD45 associated transmembrane protein LPAP.
(C) gp30/40 localizes at the cell membrane in T cells. 3 3 107 HPB-ALL (left) or TCR-deficient JRT3-T3.1 cells (right) were externally labeled with
CD3 mAb (OKT-3). Unbound antibodies were removed by washing and cells were lysed in 1% Brij58-containing buffer. Preformed immune complexes
were collected with protein A–Sepharose and subjected to in vitro kinase assay. In vitro phosphorylated proteins were subjected to reprecipitation using
protein A–Sepharose alone (lanes 1 and 11), anti-gp30/40 (lanes 2 and 12), anti-z (lanes 3 and 13), anti-TRIM (lanes 4 and 14), or CD3-e (lanes 5 and
15) antibodies. Lanes 6–10 show the same experiment as in lanes 1–5 except that in lanes 6–10 HPB-ALL cells were first lysed in digitonin and then sub-
jected to CD3-e immunoprecipitation.1187 Marie-Cardine et al.
exclusively found in the cytosolic fraction, whereas LPAP
selectively localized in the membrane preparation. Thus,
gp30/40 is an integral membrane protein.
To finally assess whether gp30/40 is expressed at the cell
surface of T lymphocytes, HPB-ALL T cells were incu-
bated on ice for 30 min with a CD3-e mAb of the IgG2a
isotype. Cells were then washed with ice-cold buffer (to
remove all unbound CD3 mAbs) and lysed in Brij58-con-
taining buffer, which preserves the association between
gp30/40 and the TCR–CD3–z complex (see Fig. 2 A). Af-
ter depletion of the nuclei, the preformed immune com-
plexes were collected using protein A–Sepharose and sub-
jected to in vitro kinase assay. The in vitro–labeled proteins
were subsequently released from the primary immunopre-
cipitates using SDS-containing buffer and subjected to a
second round of immunoprecipitation using gp30/40 anti-
serum. These secondary immunoprecipitates were separated
on reducing 14% SDS-PAGE and analyzed by autoradio-
graphy. As a positive control, we used antisera directed at
proteins that are known to associate with the TCR on the
cell surface, namely CD3-e, the z chains, and TRIM.
The left panel of Fig. 4 C demonstrates that gp30/40 co-
precipitates with cell surface–expressed CD3-e in the HPB-
ALL T cell line. This association seems to be similar to the
association that is detectable in HPB-ALL cells that are first
lysed and then subjected to CD3 immunoprecipitation
(Fig. 4 C, middle). Similar results were obtained when Jur-
kat T cells were analyzed in an identical fashion (data not
shown), whereas no specific signal was detectable in a
TCR a chain–deficient Jurkat variant (JRT3-T3.1) lacking
cell surface expression of the TCR–CD3–z complex (Fig.
4 C, right). This rules out the possibility that the externally
applied CD3 mAb passed the cell membrane. Thus, the
data shown in Fig. 4 collectively demonstrate that gp30/40
is an integral membrane protein that is expressed at the cell
surface of T cells.
Tyrosine Phosphorylation of gp30/40 after T Cell Activation.
To investigate whether gp30/40 becomes tyrosine phos-
phorylated after TCR-mediated activation of T lympho-
cytes, HPB-ALL cells were stimulated for various periods
of time with a mixture of biotinylated CD3 and CD4 mAbs
that were cross-linked on the cell surface with avidin. Sub-
sequently, cells were lysed in NP-40–containing buffer and
subjected to immunoprecipitation with anti-PTYR mAb
PY72. Immunoprecipitates were separated on SDS-PAGE
and analyzed by anti-gp30/40 Western blot. As shown in
Fig. 5 A, low amounts of constitutively tyrosine phosphor-
ylated gp30/40 are detectable in nonstimulated HPB-ALL
cells. Perhaps more importantly, the level of phosphoryla-
tion of gp30/40 strongly increased after cross-linking of the
CD3 and CD4 receptor molecules. Moreover, a dramatic
increase in gp30/40 tyrosine phosphorylation was induced
in HPB-ALL cells stimulated with pervanadate. Similar re-
sults as shown here were obtained when gp30/40 immu-
Figure 5. Tyrosine phosphorylation of gp30/40. (A) 3 3 107 HPB-ALL cells were ac-
tivated with a mixture of biotinylated CD3 (OKT-3) and CD4 (AICD4.1) mAbs fol-
lowed by cross-linking with avidin. As a positive control, cells were stimulated for 2 min
with pervanadate. Lysates were subjected to anti-PTYR immunoprecipitation (PY72)
followed by gp30/40 Western blot analysis. (B) Jurkat cells were transiently transfected
with 30 mg of plasmid coding for the CCG chimera. After overnight incubation, 2 3 106
cells were stimulated for the indicated periods of time with the clonotypic anti-TCR
mAb C305. Subsequently cells were lysed and subjected to CD8 immunoprecipitation
followed by anti-PTYR Western blotting (top). The blot was then stripped and reincu-
bated with gp30/40 antibodies (middle). Lysates corresponding to 3 3 105 cells were
separately analyzed for induction of tyrosine phosphorylation by anti-PTYR Western
blotting (bottom). (C) COS cells were transiently transfected with the cDNA constructs
depicted on top of each lane. 10% of the transfectants was analyzed by anti-PTYR West-
ern blot (top left). The blot was stripped and expression of the individual constructs as-
sessed using gp30/40, Lck, Fyn, myc (myc-ZAP70), and FLAG (FLAG-Syk) antibodies,
respectively (right). The remaining 90% of the lysates was subjected to anti-PTYR im-
munoprecipitation and analyzed by gp30/40 Western blot (bottom left).1188 The SHP2-interacting Transmembrane Adaptor Protein SIT
noprecipitates were analyzed by anti-PTYR Western blot
(data not shown).
To more directly demonstrate TCR-mediated tyrosine
phosphorylation of gp30/40, we transiently transfected Jur-
kat T cells with the above described CCG chimera. After
overnight incubation, cells were stimulated for increasing
periods of time with the clonotypic anti-TCR mAb C305
or, as a positive control, with pervanadate. Subsequently,
CD8 immunoprecipitates were prepared from resting or
activated cells and analyzed for their PTYR content by
Western blot. Fig. 5 B, top, demonstrates that the chimera
becomes rapidly phosphorylated on tyrosine residues after
TCR triggering with a maximum of phosphorylation being
observed after five min of C305 stimulation. Reprobing of
the blots with gp30/40 antiserum revealed that identical
amounts of the chimera were loaded onto the individual
lanes (Fig. 5 B, middle). In summary, the data shown in
Fig. 5, A and B, clearly demonstrate that gp30/40 repre-
sents a substrate for TCR-activated PTKs.
To analyze which tyrosine kinase can phosphorylate
gp30/40 in vivo, we transiently expressed gp30/40 in COS
cells together with plasmids coding for either Fyn, Lck,
ZAP70, and Syk or with a combination of Lck/Fyn and
ZAP70. However, in pilot experiments in which we used a
cDNA coding for wild-type gp30/40 for transfection, we
realized that detection of the transfected protein by West-
ern blotting was hardly possible because of the highly vari-
able levels of glycosylation. Therefore, we expressed a mu-
tant of gp30/40 in COS cells in which the glycosylation
site (N26) was mutated to glutamine (gp30/40-N®Q mu-
tant). Mutation of this residue resulted in expression of a
20-kD doublet that can be detected by our antiserum (Fig.
5 C, top right).
Lysates of COS cells transiently transfected with a combina-
tion of the cDNA construct coding for the gp30/40-N®Q
mutant and the above described tyrosine kinases were ana-
lyzed by anti-PTYR Western blot. At the same time, anti-
PTYR immunoprecipitates were prepared from the trans-
fected cells and investigated for the presence of tyrosine
phosphorylated gp30/40 by means of anti-gp30/40 West-
ern blotting. The left panels of Fig. 5 B demonstrate that
under these experimental conditions gp30/40 becomes ty-
rosine phosphorylated by Lck and to a stronger extent by
Fyn, but is only very weakly tyrosine phosphorylated when
the molecule is coexpressed with either ZAP70 or Syk
alone. However, when Fyn and ZAP70 are concomitantly
expressed, tyrosine phosphorylated gp30/40 migrates at a
slightly higher apparent mol wt compared with co-expres-
sion with Fyn alone. Since identical data were obtained in
three independent experiments, these findings suggest that
gp30/40 represents not only a substrate for src PTKs but
that it can also become phosphorylated by ZAP70.
Expression of gp30/40 in Jurkat Cells Inhibits TCR- and
PHA-mediated Activation of the Transcription Factor NF-AT.
To obtain initial information on the in vivo function of gp30/
40, we transiently transfected Jurkat T cells with increasing
concentrations of a plasmid coding for a full-length gp30/
40 molecule together with a luciferase reporter gene con-
struct driven by a triplicated NF-AT binding site of the hu-
man IL-2 promoter (38). At 18 h of transfection, expres-
sion of transfected gp30/40 was determined by Western
blotting (Fig. 6 A, insets), and cells were stimulated for an
additional 6 h with either the clonotypic anti-TCR mAb
C305 or the polyclonal mitogen PHA. As shown in Fig. 6
A, overexpression of SIT inhibited both PHA- and TCR-
mediated induction of NF-AT activity in a dose-dependent
fashion. Thus, compared with the vector control, a signifi-
cant reduction of the signals was already observed with 5 mg
of transfected gp30/40 cDNA, whereas transfection with
30 mg cDNA resulted in a 91% reduction of the PHA
signal and a 76% reduction of the TCR-induced NF-AT
activity, respectively. Similarly, transient overexpression of
gp30/40 in Jurkat cells resulted in a strong inhibition of the
CD2-mediated pathway of T cell activation (data not
shown).
To assess whether the cytoplasmic portion of gp30/40
was responsible for the inhibitory effect of gp30/40 on the
TCR- and PHA-mediated pathways of T cell activation,
we transiently transfected a truncated mutant of gp30/40
into Jurkat cells in which a FLAG epitope was introduced
at H62 of gp30/40 followed by a STOP codon (gp30/40-
STOP mutant). The Fig. 6 B, left, demonstrates that, in
contrast to the wild-type protein, expression of the gp30/
40-STOP mutant exerts no negative regulatory effect on
NF-AT activity. This indicates that the negative regulatory
role of wild-type gp30/40 on TCR- and PHA-induced
transcriptional activity of NF-AT requires an intact cyto-
plasmic tail. Moreover, the finding that stimulation of the
transfectants with a combination of PMA plus ionomycin
bypassed gp30/40-mediated inhibition of NF-AT activa-
tion (Fig. 6 B, middle) strongly suggests that gp30/40 proba-
bly regulates a proximal signaling event(s) of human T cell
activation (see below).
Inhibition of TCR- and PHA-mediated induction of
NF-AT activity was also observed when the above described
CCG chimera (see Figs. 2 and 4) was expressed in Jurkat
cells, whereas expression of a truncated version in which S71
of gp30/40 was mutated to a STOP-codon (CC-STOP chi-
mera), or of a control chimera (consisting of the extracellular
domain of human HLA-A2 fused to a full length TRIM
molecule, Ch_F), did not affect signaling (Fig. 6 C). Col-
lectively, these data indicate that gp30/40, when overex-
pressed in Jurkat T cells, acts as a negative regulator for
both TCR- and PHA-mediated transcriptional activity of
NF-AT.
To more precisely localize where gp30/40 exerts its
function during TCR-mediated signaling, we transfected a
gp30/40 cDNA together with the NF-AT–driven reporter
construct into a Jurkat variant stably expressing the human
muscarinic receptor type 1 (J.HM1.2.2 cells). Stimulation
of this heterologous receptor with carbachol results in acti-
vation of PLC via a G protein–coupled mechanism that
does not involve PTK-mediated signaling (27–30). Fig. 6 D
demonstrates that overexpression of gp30/40 in J.HM1.2.2
cells inhibited CD3-mediated induction of NF-AT activity
to a similar extent as in wild-type Jurkat cells. Importantly,1189 Marie-Cardine et al.
however, in the same cells gp30/40 did not influence sig-
naling mediated via the muscarinic receptor. Thus, gp30/
40 probably regulates TCR-mediated induction of NF-AT
activity via a mechanism that is located upstream of activa-
tion of PLC.
gp30/40 Associates with the SHP2 Tyrosine Phosphatase af-
ter T Cell Activation. As reported above (Fig. 1 B), gp30/40
possesses a putative ITIM in its cytoplasmic tail (VKY148
SEV) (35, 36). Given the strong negative regulatory effect on
the induction of NF-AT activity after overexpression of
gp30/40 or the CCG chimera, we next investigated whether
gp30/40, in its tyrosine phosphorylated state, has the capac-
ity to recruit SH2 domain–containing cytoplasmic phospha-
tases like SHP1, SHP2, or SHIP to the cell membrane. These
phosphatases have been demonstrated to preferentially bind
to ITIMs via their SH2 domains and seem to be involved
in both positive and negative regulatory signaling pathways
in lymphocytes (39–45).
Jurkat cells were stimulated for increasing periods of time
with either C305 mAb or PHA, washed, and lysed in NP-40–
containing buffer. Subsequently, anti-gp30/40 immuno-
precipitates were prepared and analyzed for coprecipitation
of the above phosphatases by Western blotting. In several
individual experiments we were unable to demonstrate a
specific interaction of gp30/40 with SHP1 or SHIP (data not
shown). However, as demonstrated in Fig. 7 A, appreciable
levels of SHP2 coprecipitated with gp30/40 after TCR-
(left) as well as PHA- (right) mediated activation of Jurkat
cells.
The specificity of interaction between gp30/40 and
SHP2 was further proven in Jurkat cells treated with per-
vanadate. There SHP2 was found to specifically coprecipi-
Figure 6. gp30/40 is involved in the regulation of T cell activation. (A) 2 3 107 Jurkat cells were transfected with increasing concentrations of wild-
type gp30/40 cDNA and reporter construct driven by a triplicated NF-AT binding site of the human IL-2 promoter. An appropriate amount of empty
vector DNA was added to all samples to yield equal amounts of transfected DNA. Lysates corresponding to 5 3 105 cells were analyzed for expression of
gp30/40 by Western blot analysis. Note that due to the low levels of gp30/40 expression the protein is not detected in nontransfected cells. At 18 h after
transfection cells were stimulated with anti-TCR mAb C305 or with PHA. 6 h later luciferase activity was determined. Depicted are relative responses
which were obtained by the following calculation: luciferase units produced by TCR or PHA-stimulation divided by luciferase units produced by stim-
ulating the cells with a combination of PMA and ionomycin (5 maximal response) 3 100. (B) Jurkat cells were transiently transfected with 20 mg empty
vector (BOS), wild-type gp30/40 or the gp30/40-STOP cDNAs in combination with the above reporter construct and processed as in A (left). Relative
luciferase units after stimulation of the transfectants with a combination of PMA and ionomycin (middle). Expression of the constructs was verified by
gp30/40 (wild-type protein) or FLAG (gp30/40-STOP) Western blot analysis (right). (C) 2 3 107 Jurkat cells were transfected with empty vector or
with plasmids coding for the CCG or the CC-STOP chimeras together with the NF-AT–driven luciferase reporter gene construct. A chimeric TRIM
molecule (Ch_F) served as a control. The experiment was then performed as described in A. (D) J.HM1.2.2 cells were transiently transfected with 25 mg
wild-type gp30/40 cDNA and then stimulated with either anti-CD3 mAb OKT3 or with carbachol followed by determination of luciferase activity. Ex-
pression of the construct was determined by gp30/40 Western blot analysis. (E) cDNA constructs used for the experiments shown in Fig. 6.1190 The SHP2-interacting Transmembrane Adaptor Protein SIT
tate with gp30/40 (Fig. 7 B, left), whereas the phosphatase
failed to interact with the recently cloned transmembrane
adaptor protein TRIM (which does not possess an ITIM).
Conversely, as previously reported, the p85 subunit of
PI3-K associated inducibly with TRIM (Fig. 7 B, right),
but not with gp30/40 (probably because gp30/40 lacks the
YxxM-motif, which mediates the binding between p85
and TRIM [reference 20]). In summary, the data shown in
Fig. 7, A and B, indicate that gp30/40 specifically associates
with SHP2 after T cell activation. Therefore, we termed
the gp30/40 protein SIT (SHP2-interacting transmem-
brane adaptor protein).
To investigate whether the interaction between SHP2
and SIT indeed involves the ITIM, we transiently expressed
in Jurkat cells the above shown CCG chimera or mutants
of this chimera in which either the complete intracellular
portion of SIT was deleted (CC-STOP chimera) or in which
the tyrosine residue of the ITIM was mutated to phenylala-
nine (CC-ITIM chimera). By expressing CD8/CD8/SIT
chimeras instead of mutated SIT molecules, we could largely
rule out the possibility that the transfected chimera forms
disulfide-linked heterodimers with endogenous SIT and
thus generates false positive results during our experiments.
Moreover, the use of the extracellular domain of CD8 al-
lowed us to perform immunoprecipitation experiments us-
ing a mouse CD8 mAb, thus preventing the possibility that
the immunoprecipitates become contaminated with endog-
enously expressed wild-type SIT molecules.
Fig. 7 C demonstrates that, as expected, a CD8 immuno-
precipitate prepared from either nonstimulated or pervana-
date-treated wild-type Jurkat cells (lacking CD8 expression)
did not contain detectable levels of SHP2. However, when
Figure 7. Interaction between gp30/40 and SHP2. (A) 3 3 107 Jurkat cells/lane were activated with mAb C305 or with PHA. Lysates were subjected
to anti-gp30/40 immunoprecipitation followed by blotting with SHP2 mAb. PI, preimmune serum. (B) 3 3 107 Jurkat cells were left unstimulated or
were treated for 2 min with pervanadate. Lysates were subjected to gp30/40 (left) or TRIM immunoprecipitation (right). The precipitates were blotted
onto nitrocellulose, which was first incubated with an antibody directed at the 85 kD regulatory subunit of PI3-K (p85), then stripped and reincubated
with SHP2 mAb (SHP2). (C) 5 3 106 untransfected Jurkat cells or Jurkat cells transiently transfected with cDNAs coding for the CCG, the CCS (STOP)
or the CC-ITIM (ITIM) chimeras were left untreated or were treated for 2 min with pervanadate. Lysates were subjected to CD8 immunoprecipitation
followed by SDS-PAGE and SHP2 Western blot analysis. Blots were stripped and reincubated with SIT antiserum. Note that expression of the CCS
mutant could not be assessed by SIT Western blot analysis due to lack of reactive epitopes. Expression of this construct as well as of the CCG construct
was verified by FACS® analysis of the transfectant using a CD8 mAb (data not shown). (D) (Top) Jurkat cells were transiently transfected with cDNAs
coding for wild type SIT or the gp30/40-ITIM mutant. TCR- and PHA-mediated induction of NF-AT activity was then determined as described
above. Expression of the constructs was assessed by SIT immunoblotting. (Bottom) The same experiment using cDNA constructs coding for the CCG
and the CC-ITIM chimeras, respectively. Expression of the chimeric molecules was analyzed by indirect immunofluorescence using a CD8 mAb.1191 Marie-Cardine et al.
CD8 immunoprecipitates were prepared from cells that had
been transiently transfected with the CCG chimera, large
amounts of SHP2 were detectable in the precipitates ob-
tained from pervanadate-treated cells. That coprecipitation
of SHP2 by the CCG chimera requires the presence of the
cytoplasmic part of SIT was evident from the observation
that SIT/SHP2 interaction was completely lost when the
cells were transfected with the CC-STOP chimera lacking
the cytoplasmic portion of SIT. Perhaps more importantly,
coprecipitation of SHP2 was also almost completely lost
(.90% reduction as judged from densitometric analysis of
the shown blot) when Jurkat cells were transfected with the
CC-ITIM chimera. The latter finding formally proves that
the interaction between SIT and SHP2 requires a function-
ally intact ITIM.
We next investigated whether loss of interaction be-
tween SIT and SHP2 would abolish the inhibition of TCR-
and/or PHA-mediated induction of NF-AT activity ex-
erted by wild-type SIT and the CCG chimera. As shown
in Fig. 7 D, overexpression of the gp30/40-ITIM mutant
(top) or of the CC-ITIM chimera (bottom) downregulates
both TCR- and PHA-mediated induction of NF-AT ac-
tivity as observed for the wild-type protein. Thus, although
expression of an intact ITIM is required for the interaction
of SIT with SHP2, it does not mediate the negative regula-
tory effect of wild-type SIT or of the CCG chimera on
TCR- and PHA-mediated induction of NF-AT activity.
Discussion
In this report we describe the purification, nanoelectro-
spray sequencing, molecular cloning, and functional char-
acterization of a novel transmembrane adaptor molecule
that we have termed SIT (SHP2-interacting transmem-
brane adaptor protein). As previously reported, SIT copuri-
fied with a recently cloned disulfide-linked dimer called
TRIM (20). Most likely the expression of SIT in T lym-
phocytes was not appreciated earlier because of the gener-
ally low levels of expression of SIT in lymphocytes and its
particular biochemical properties (high levels of glycosyla-
tion combined with variable levels of phosphorylation),
which largely impair the detectability of the protein by
biochemical standard methods (for examples, see Figs. 2 A
and 4 B).
SIT represents a disulfide-linked dimer that is preferen-
tially expressed in T and B lymphocytes. Thus, within the
lymphatic system, expression of SIT seems not to be re-
stricted to T cells as was recently reported for LAT (21, 22)
and TRIM (20). SIT also differs from LAT and TRIM by
the presence of a single N-linked glycosylation site that is
located directly adjacent to the cysteine residue that is re-
sponsible for dimerization. In fact, the cysteine residue is
part of the glycosylation recognition sequence NxT. De-
glycosylation experiments indicated that the carbohydrate
moiety of SIT accounts for z20 kD of mol wt (Fig. 2 C).
Whether the carbohydrate chain represents a binding do-
main for an extracellular ligand is unknown at present but
represents a good possibility.
SIT becomes tyrosine phosphorylated after TCR-medi-
ated activation of HPB-ALL or Jurkat cells (Fig. 5, A and
B). Coexpression experiments performed in COS cells re-
vealed that SIT represents a substrate for src kinases, most
notably Fyn (Fig. 5 C). However, in contrast to TRIM,
which is exclusively phosphorylated by src kinases (20), and
LAT, which is probably a selective substrate for ZAP70
(22), SIT phosphorylation seems to be mediated by both
src and syk PTKs. Thus, when ZAP70 and Fyn are coex-
pressed in COS cells, SIT reproducibly migrates at a
slightly higher apparent mol wt than when expressed with
Fyn alone. These findings could indicate that SIT phos-
phorylation occurs in two subsequent steps that are medi-
ated by src and syk PTKs, respectively.
One attractive model would be that, immediately after
triggering of the TCR, SIT becomes phosphorylated by an
src PTK. This phosphorylation event could induce a con-
formational change of SIT, resulting in accessibility of an-
other tyrosine residue representing a phosphorylation site
for ZAP70. To investigate this possibility it will be neces-
sary to generate variants of the gp30/40-N®Q mutant in
which individual tyrosine residues are mutated and to in-
vestigate whether coexpression of Fyn and ZAP70 still pro-
duces a higher mol wt form of the molecule. However,
consistent with a two-step model for SIT tyrosine phos-
phorylation is our observation that the apparent mol wt of
tyrosine phosphorylated wild-type SIT (although difficult
to assess because of its heavy glycosylation) also increases af-
ter prolonged stimulation of Jurkat and HPB-ALL cells
(our unpublished data).
Overexpression studies performed in Jurkat cells with
the intention to elucidate the function of SIT indicated that
wild-type SIT and the CCG chimera strongly downregu-
lated both TCR- and PHA-mediated activation of NF-AT
(Fig. 6, A–C). Inhibition of NF-AT activity required the
presence of the cytoplasmic portion of SIT as judged from
analysis of Jurkat cells transfected with plasmids coding for
versions of SIT lacking the cytoplasmic domain (gp30/40-
STOP and CCS chimera, Fig. 6, B and C). Perhaps more
importantly, the observation that the inhibitory effect of
SIT could be bypassed with a combination of PMA and
ionomycin (Fig. 6 B) strongly suggested that SIT controls
an early step of T cell activation. This assumption was con-
firmed in a Jurkat variant that coexpresses the human mus-
carinic receptor type 1 and the TCR–CD3 complex. Both
types of receptors activate PLC via distinct mechanisms. Thus,
the TCR couples to PLC via the tyrosine kinase pathway.
In contrast, the muscarinic receptor activates PLC via a
pathway involving a heterotrimeric G protein. Our finding
that overexpression of SIT alters signaling via the TCR but
not via the muscarinic receptor (Fig. 6 D) thus indicates
that SIT exerts its functional effect upstream of PLC activa-
tion and that it selectively regulates signaling via the PTK
pathway. However, further investigations are required to
elucidate which of the most proximal steps of TCR-medi-
ated T cell activation are controlled by SIT.
One major candidate for mediating the inhibitory func-
tion of SIT was tyrosine 148 which is a component of a1192 The SHP2-interacting Transmembrane Adaptor Protein SIT
putative ITIM. ITIMs are known to mediate noncovalent
interactions with SH2-domain containing phosphatases such
as SHP1, SHP2 or SHIP (35, 36, 39–45). Indeed, coprecipi-
tation experiments demonstrated that SIT specifically inter-
acts with SHP2 after TCR- and PHA-mediated activation of
Jurkat cells (Fig. 7 A). The association between SHP2 and
SIT was dependent on phosphorylation of Y148 as judged
from a transient expression experiment which revealed that a
SIT mutant in which Y148 was mutated to phenylalanine
(CC-ITIM mutant) had largely lost its ability to recruit
SHP2 (Fig. 7 B). The residual binding of SHP2 to the CC-
ITIM chimera (less than 10%) might indicate that besides
Y148 a second tyrosine residue of SIT is involved in the in-
teraction between the two molecules and that SHP2 uses
both SH2-domains to bind to SIT. Such a mode of interac-
tion would be in line with recently reported data describing
the crystal structure of SHP2 (46). Experiments are under-
way to prove this possibility.
The finding that SIT selectively associates with SHP2 in
Jurkat cells might be surprising in light of previous data in-
dicating that the binding motifs for the SH2-domains of
SHP1, SHP2 and SHIP are quite similar. Indeed, coprecip-
itation experiments performed on pervanadate treated Jur-
kat cells revealed that tyrosine phosphorylated SIT strongly
binds to the isolated SH2-domains of all three phosphatases
in vitro (our unpublished observations). The selective in vivo
association of SHP2 and SIT could thus result from a selec-
tive colocalization of both molecules within the cell. An-
other possibility would be that the presence of the posi-
tively charged lysine residue in the 21 position relative to
Y148 selects for a preferential association between SIT and
SHP2.
Importantly, despite that fact that the ITIM of SIT re-
cruits SHP2 and that mutation of Y148 in the ITIM almost
completely ablated SHP2 binding, overexpression of a
SIT-ITIM or a CC-ITIM mutant still resulted in inhibition
of TCR- and PHA-mediated induction of NF-AT activity
that was indistinguishable from the functional effect ex-
erted by the wild-type protein (Fig. 7 D). These data col-
lectively suggest that, although expression and tyrosine
phosphorylation of the ITIM of SIT is required to mediate
its association with SHP2, the binding of SHP2 to SIT per
se is not responsible for the inhibitory capacity of the pro-
tein under the experimental conditions used in this study.
The finding that inhibition of binding of SHP2 to SIT
does not rescue NF-AT activation could suggest that SIT
serves several functions during T cell activation. One func-
tion could be the regulation of the transcriptional activity
of NF-AT. In this regard SIT could serve as a gate-keeping
molecule that helps to arrest nonprimed T lymphocytes in
a quiescent state. Which part of the cytoplasmic domain of
SIT is involved in this potential function requires further
investigation. Preliminary data indicate that a mutant of the
CCG chimera lacking the 50 COOH-terminal aa of the
cytoplasmic domain no longer interferes with TCR-medi-
ated induction of NF-AT activity (our unpublished obser-
vation). This strongly suggests that the 50 COOH-terminal
aa of SIT are mainly responsible for its functional effect (at
least with regard to the induction of NF-AT). However,
the elucidation of the question, which of the 50 COOH-
terminal aa are responsible for inhibition of NF-AT activ-
ity, requires establishing additional truncation mutants of SIT
or SIT mutants in which the two COOH-terminal tyro-
sine-based signaling motifs (the Y169ASV motif and the
Y188ANS motif, see below) would be individually or con-
comitantly mutated. Experiments addressing these ques-
tions are being performed.
Additional roles for SIT (distinct from control of NF-AT
activity) could emerge from its interaction with SHP2.
Since it has been proposed that SHP2 is involved in both
negative and positive regulatory pathways of T cell activa-
tion, further investigations are required to elucidate the
consequences of SHP2-binding to SIT on T cell activation.
It is important to note that further functions for SIT
could result from the existence of the four tyrosine-based
signaling motifs in its cytoplasmic domain that are unre-
lated to ITIMs and also do not represent ITAMs (Fig. 1 A).
Although these motifs are potential binding sites for the
SH2 domain of Grb2 (Y90GNL and Y188ANS) and for src
kinases (Y127TSL and Y169ASV), thus far we have not been
able to establish a direct interaction between SIT and these
signal-transducing polypeptides. Nevertheless, it is tempt-
ing to speculate that the four tyrosine-based binding motifs
in the cytoplasmic domain of SIT contribute to its function
in vivo.
The three transmembrane adaptor proteins (LAT, TRIM
and SIT) identified thus far altogether possess 22 potential
tyrosine-based signaling motifs that probably mediate tyrosine
phosphorylation–dependent interactions with SH2 domain–
containing intracellular signaling molecules. The presence
of these multiple tyrosine-based signaling motifs close to
the membrane not only offers an explanation how intracel-
lular signal transducers (e.g., PLCg1, Grb2, PI3-K, SHP2,
etc.) are recruited to the plasma membrane but also pro-
vides the T cell with potent tools for fine tuning T cell ac-
tivation depending on the quality, quantity, and length of
TCR occupancy. In addition, transmembrane adaptor
molecules could also serve to integrate signaling events me-
diated via secondary signaling receptors.
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